Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy

Androgen deprivation therapy is a standard of care for metastatic prostate cancer. A paradoxical approach utilizing high doses of testosterone in castration‐resistant prostate cancer patients demonstrated clinical responses. Here, we report on four heavily pretreated Japanese patients (including one...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoshi, Senji, Bilim, Vladimir, Hoshi, Kiyotsugu, Nakagawa, Takuya, Sato, Sadanobu, Sakagami, Rie, Konno, Masato, Kudo, Takashi, Numahata, Kenji, Sasagawa, Isoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829667/
https://www.ncbi.nlm.nih.gov/pubmed/35154735
http://dx.doi.org/10.1002/ccr3.5433
_version_ 1784648118608855040
author Hoshi, Senji
Bilim, Vladimir
Hoshi, Kiyotsugu
Nakagawa, Takuya
Sato, Sadanobu
Sakagami, Rie
Konno, Masato
Kudo, Takashi
Numahata, Kenji
Sasagawa, Isoji
author_facet Hoshi, Senji
Bilim, Vladimir
Hoshi, Kiyotsugu
Nakagawa, Takuya
Sato, Sadanobu
Sakagami, Rie
Konno, Masato
Kudo, Takashi
Numahata, Kenji
Sasagawa, Isoji
author_sort Hoshi, Senji
collection PubMed
description Androgen deprivation therapy is a standard of care for metastatic prostate cancer. A paradoxical approach utilizing high doses of testosterone in castration‐resistant prostate cancer patients demonstrated clinical responses. Here, we report on four heavily pretreated Japanese patients (including one patient on hemodialysis) successfully treated with supra‐physiological doses of testosterone.
format Online
Article
Text
id pubmed-8829667
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88296672022-02-11 Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy Hoshi, Senji Bilim, Vladimir Hoshi, Kiyotsugu Nakagawa, Takuya Sato, Sadanobu Sakagami, Rie Konno, Masato Kudo, Takashi Numahata, Kenji Sasagawa, Isoji Clin Case Rep Case Reports Androgen deprivation therapy is a standard of care for metastatic prostate cancer. A paradoxical approach utilizing high doses of testosterone in castration‐resistant prostate cancer patients demonstrated clinical responses. Here, we report on four heavily pretreated Japanese patients (including one patient on hemodialysis) successfully treated with supra‐physiological doses of testosterone. John Wiley and Sons Inc. 2022-02-10 /pmc/articles/PMC8829667/ /pubmed/35154735 http://dx.doi.org/10.1002/ccr3.5433 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Hoshi, Senji
Bilim, Vladimir
Hoshi, Kiyotsugu
Nakagawa, Takuya
Sato, Sadanobu
Sakagami, Rie
Konno, Masato
Kudo, Takashi
Numahata, Kenji
Sasagawa, Isoji
Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy
title Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy
title_full Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy
title_fullStr Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy
title_full_unstemmed Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy
title_short Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy
title_sort clinical response in metastatic castration‐resistant prostate cancer (mcrpc) cases treated with supra‐physiological doses of testosterone: bipolar androgen therapy
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829667/
https://www.ncbi.nlm.nih.gov/pubmed/35154735
http://dx.doi.org/10.1002/ccr3.5433
work_keys_str_mv AT hoshisenji clinicalresponseinmetastaticcastrationresistantprostatecancermcrpccasestreatedwithsupraphysiologicaldosesoftestosteronebipolarandrogentherapy
AT bilimvladimir clinicalresponseinmetastaticcastrationresistantprostatecancermcrpccasestreatedwithsupraphysiologicaldosesoftestosteronebipolarandrogentherapy
AT hoshikiyotsugu clinicalresponseinmetastaticcastrationresistantprostatecancermcrpccasestreatedwithsupraphysiologicaldosesoftestosteronebipolarandrogentherapy
AT nakagawatakuya clinicalresponseinmetastaticcastrationresistantprostatecancermcrpccasestreatedwithsupraphysiologicaldosesoftestosteronebipolarandrogentherapy
AT satosadanobu clinicalresponseinmetastaticcastrationresistantprostatecancermcrpccasestreatedwithsupraphysiologicaldosesoftestosteronebipolarandrogentherapy
AT sakagamirie clinicalresponseinmetastaticcastrationresistantprostatecancermcrpccasestreatedwithsupraphysiologicaldosesoftestosteronebipolarandrogentherapy
AT konnomasato clinicalresponseinmetastaticcastrationresistantprostatecancermcrpccasestreatedwithsupraphysiologicaldosesoftestosteronebipolarandrogentherapy
AT kudotakashi clinicalresponseinmetastaticcastrationresistantprostatecancermcrpccasestreatedwithsupraphysiologicaldosesoftestosteronebipolarandrogentherapy
AT numahatakenji clinicalresponseinmetastaticcastrationresistantprostatecancermcrpccasestreatedwithsupraphysiologicaldosesoftestosteronebipolarandrogentherapy
AT sasagawaisoji clinicalresponseinmetastaticcastrationresistantprostatecancermcrpccasestreatedwithsupraphysiologicaldosesoftestosteronebipolarandrogentherapy

Ejemplares similares